These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7879247)

  • 41. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients.
    Danziger-Isakov LA; DelaMorena M; Hayashi RJ; Sweet S; Mendeloff E; Schootman M; Huddleston CB; DeBaun MR
    Transplantation; 2003 May; 75(9):1538-43. PubMed ID: 12792511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ganciclovir/acyclovir prophylaxis reduces the incidence of cytomegalovirus infections in pancreas transplant recipients.
    Harland RC; Vernon WB; Bunzendahl H; Thompson JK; Lawrence C; Bollinger RR
    Transplant Proc; 1994 Apr; 26(2):432-3. PubMed ID: 8171488
    [No Abstract]   [Full Text] [Related]  

  • 43. The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients.
    Nogueira E; Ozaki KS; Tomiyama H; Granato CF; Camara NO; Pacheco-Silva A
    Int Immunopharmacol; 2006 Dec; 6(13-14):2031-7. PubMed ID: 17161359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prophylactic treatment with ganciclovir for cytomegalovirus infection in heart transplantation.
    Laske A; Gallino A; Mohacsi P; Bauer EP; Carrel T; von Segesser LK; Turina MI
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1170-3. PubMed ID: 1846456
    [No Abstract]   [Full Text] [Related]  

  • 47. Effective strategies to prevent cytomegalovirus disease after renal transplantation.
    Chapman JR
    Transplant Proc; 2000 Nov; 32(7):1508-9. PubMed ID: 11119809
    [No Abstract]   [Full Text] [Related]  

  • 48. Use of cytomegalovirus immune globulin.
    Snydman DR
    Clin Pharm; 1992 Aug; 11(8):674-5. PubMed ID: 1324822
    [No Abstract]   [Full Text] [Related]  

  • 49. Chronic rejection in kidney transplant patients receiving cytomegalovirus prophylaxis with acyclovir.
    Birkeland SA; Rohr N; Elbirk A; Jørgensen KA
    Transplant Proc; 1995 Jun; 27(3):2040-1. PubMed ID: 7792878
    [No Abstract]   [Full Text] [Related]  

  • 50. Cytomegalovirus infection-enhanced chronic rejection in the rat is prevented by antiviral prophylaxis.
    Tikkanen J; Kallio E; Pulkkinen V; Bruggeman C; Koskinen P; Lemström K
    Transplant Proc; 2001; 33(1-2):1801. PubMed ID: 11267518
    [No Abstract]   [Full Text] [Related]  

  • 51. CMV prophylaxis: what is valid in 2002?
    Heemann U; Wenzel RR
    Nephrol Dial Transplant; 2002 Apr; 17(4):556-9. PubMed ID: 11917045
    [No Abstract]   [Full Text] [Related]  

  • 52. IGIV prophylaxis therapy for CMV in renal transplant recipients.
    Mendoza M
    ANNA J; 1993 Dec; 20(6):691-2. PubMed ID: 8267416
    [No Abstract]   [Full Text] [Related]  

  • 53. Desensitization during renal transplantation.
    Fourtounas C; Mouzaki A; Vlachojannis JG
    N Engl J Med; 2008 Oct; 359(16):1731; author reply 1731-2. PubMed ID: 18923177
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical significance of positive cytomegalovirus cultures from urine and/or blood.
    Kokado Y; Takahara S; Takano Y; Kameoka H; Ishibashi M; Okuyama A; Tanaka K; Oosumi Y; Okada S; Sonoda T
    Transplant Proc; 1992 Aug; 24(4):1562-4. PubMed ID: 1323156
    [No Abstract]   [Full Text] [Related]  

  • 55. Quo vadis? The clinical dilemma of simultaneous cytomegalovirus infection and steroid-resistant rejection.
    van den Berg AP; Tegzess AM; Scholten-Sampson A; van der Giessen M; The TH; van Son WJ
    Transplantation; 1991 Dec; 52(6):1081-3. PubMed ID: 1661036
    [No Abstract]   [Full Text] [Related]  

  • 56. Cytomegalovirus hyperimmune globulin.
    Snydman DR
    Pediatr Infect Dis J; 1992 Sep; 11(9):777-8. PubMed ID: 1333068
    [No Abstract]   [Full Text] [Related]  

  • 57. The use of intravenous gamma globulin for CMV prophylaxis.
    Leszczynski J; Gupta CK; Siber GR
    Transplantation; 1993 Sep; 56(3):765. PubMed ID: 8212176
    [No Abstract]   [Full Text] [Related]  

  • 58. Cytomegalovirus hyperimmune globulin: who needs it?
    Adler SP
    Pediatr Infect Dis J; 1992 Apr; 11(4):266-9. PubMed ID: 1314376
    [No Abstract]   [Full Text] [Related]  

  • 59. Complementary data about the inhibitory effects of intravenous immunoglobulins in vitro and in vivo.
    Casadei DH; Rial MC; Raimondi E; Goldberg J; Argento J; Haas E
    Transplantation; 1997 Apr; 63(8):1191-2. PubMed ID: 9133486
    [No Abstract]   [Full Text] [Related]  

  • 60. Neutralizing activity of immunoglobulin preparations.
    Adler SP
    Transplantation; 2012 Feb; 93(4):e14; author reply e14. PubMed ID: 22314308
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.